Prognostic impact of baseline tumour immune infiltrate on disease-free survival in patients with completely resected, BRAF(v600) mutation-positive melanoma receiving adjuvant vemurafenib

首页> 外文期刊>Annals of oncology: official journal of the European Society for Medical Oncology >Prognostic impact of baseline tumour immune infiltrate on disease-free survival in patients with completely resected, BRAF(v600) mutation-positive melanoma receiving adjuvant vemurafenib

【24h】

Prognostic impact of baseline tumour immune infiltrate on disease-free survival in patients with completely resected, BRAF(v600) mutation-positive melanoma receiving adjuvant vemurafenib

机译：基线肿瘤免疫浸润对完全切除的患者的无疾病存活的预后影响，BRAF（V600）突变阳性黑素瘤接受佐剂vemureafenib

获取原文

获取原文并翻译 | 示例

获取外文期刊封面封底 >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

Background: We conducted a retrospective exploratory analysis to evaluate the effects of baseline tumour immune infiltrate on disease-free survival (DFS) outcomes in patients with fully resected stage IIC-IIIC melanoma receiving adjuvant vemurafenib monotherapy or placebo in the BRIM8 study.

机译：背景：我们进行了回顾性探索性分析，以评估基线肿瘤免疫浸润对在Brim8研究中接受佐剂vemureafenib单疗法或安慰剂的患者的无疾病存活（DFS）结果。

著录项

来源
《Annals of oncology: official journal of the European Society for Medical Oncology》 |2020年第1期|共7页
作者

展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类肿瘤学;
关键词
adjuvant therapy; melanoma; vemurafenib;

机译：佐剂疗法;黑色素瘤;vemurafenib;

相似文献

外文文献
专利

1. Prognostic impact of baseline tumour immune infiltrate on disease-free survival in patients with completely resected, BRAF(v600) mutation-positive melanoma receiving adjuvant vemurafenib [J] . Annals of oncology: official journal of the European Society for Medical Oncology . 2020,第1期

机译：基线肿瘤免疫浸润对完全切除的患者的无疾病存活的预后影响，BRAF（V600）突变阳性黑素瘤接受佐剂vemureafenib
2. Adjuvant vemurafenib in resected, BRAF(V600) mutation-positive melanoma (BRIM8): a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial [J] . Maio Michele, Lewis Karl, Demidov Lev, The lancet oncology . 2018,第4期

机译：佐剂vemurafenib在切除，BRAF（V600）突变阳性黑色素瘤（Brim8）：随机，双盲，安慰剂控制，多期，第3阶段试验
3. Effect of concomitant dosing with acid-reducing agents and vemurafenib dose on survival in patients with BRAF(V600) mutation-positive metastatic melanoma treated with vemurafenib +/- cobimetinib [J] . Lewis Karl, Hauschild Axel, Larkin James, European journal of cancer: official journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR) . 2019,第期

机译：用vemurafenib +/- cobimetinib处理的BRAF（v600）突变阳性转移性黑素瘤生存伴酸还原剂和vemureafenib剂量的疗效
4. Longer Follow-Up Confirms Relapse-Free Survival Benefit With Adjuvant Dabrafenib Plus Trametinib in Patients With Resected BRAF V600–Mutant Stage III Melanoma [O] . Axel Hauschild, Reinhard Dummer, Dirk Schadendorf, -1

机译：更长的随访时间证实BRAF V600–Mutant III期恶性黑色素瘤切除术后辅佐达拉非尼+曲美替尼可无复发生存
5. Cost-Effectiveness Analysis of Dabrafenib Plus Trametinib and Vemurafenib as First-Line Treatment in Patients with BRAF V600 Mutation-Positive Unresectable or Metastatic Melanoma in China [O] . Tianfu Gao, Jia Liu, Jing Wu 2021

机译：Dabrafenib Plus Trametinib和Vemureafenib的成本效果分析作为BRAF V600突变阳性不可切除或转移黑素瘤的一线治疗

Prognostic impact of baseline tumour immune infiltrate on disease-free survival in patients with completely resected, BRAF(v600) mutation-positive melanoma receiving adjuvant vemurafenib

摘要

著录项

相似文献

相关主题

期刊订阅